Antibody Opportunities
This article was originally published in Start Up
Executive Summary
Antibodies are driving valuations at many public companies--and the aspirations of start-ups with new means of generating, tailoring and harnessing the proteins.
You may also be interested in...
Anaptys Biosciences Inc.
According to the CEO of Anaptys Biosciences, therapeutic antibodies will continue to be the single largest growing segment in pharmaceuticals, but the number of companies providing solutions in this area is decreasing following a number of acquisitions. Anaptys will fill the gap with its somatic hypermutation technology platform for therapeutic antibody discovery and optimization. The platform replicates the natural process of mutagenesis occurring in B cells as part of the immune response, involving steps of immunoglobulin recombination, mutation, affinity maturation and selection.
Drug Delivery: Moving from Platform to Product
The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.
Drug Delivery: Moving from Platform to Product
The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.